Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC

The subjects of this study are patients with unresectable stage III non-small cell lung cancer (NSCLC) who have EGFR mutations.

Participants needed: 160
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Peng ZhangUpdated: Aug 3, 2026Locations: 1
Eligibility criteria

NSCLC patient with EGFR sensitive mutation as confirmed by needle biopsy; [+9]

The patient has undergone any systemic anti-cancer treatment for NSCLC, includin... [+9]

Read more
Status: Recruiting

Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

This study targeted patients with resectable stage II-IIIA non-small cell lung cancer with EGFR mutation

Participants needed: 60
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Peng ZhangUpdated: Jan 6, 2025Locations: 1
Eligibility criteria

NSCLC patient with EGFR sensitive mutation as confirmed by needle biopsy; [+9]

The patient has undergone any systemic anti-cancer treatment for NSCLC, includin... [+9]

Read more
Status: Recruiting

Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis

To evaluate the efficacy and safety of methylprednisolone combined with the JAK inhibitor abxitinib and tofacitinib in the treatment of toxic epidermal necrolysis

Participants needed: 30
Trial details
Phase: Early Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: Peng ZhangUpdated: Nov 28, 2023Locations: 1
Eligibility criteria

Age 18 and above. [+5]

History of allergy to JAK inhibitors. [+10]

Read more